Ikena Oncology (IKNA) Competitors $1.71 -0.02 (-1.16%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends IKNA vs. VOR, XLO, IVA, QTTB, DSGN, KOD, CYRX, CMPS, SAGE, and VYGRShould you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include Vor Biopharma (VOR), Xilio Therapeutics (XLO), Inventiva (IVA), Q32 Bio (QTTB), Design Therapeutics (DSGN), Kodiak Sciences (KOD), Cryoport (CYRX), COMPASS Pathways (CMPS), Sage Therapeutics (SAGE), and Voyager Therapeutics (VYGR). Ikena Oncology vs. Vor Biopharma Xilio Therapeutics Inventiva Q32 Bio Design Therapeutics Kodiak Sciences Cryoport COMPASS Pathways Sage Therapeutics Voyager Therapeutics Ikena Oncology (NASDAQ:IKNA) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, community ranking, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations. Do institutionals & insiders have more ownership in IKNA or VOR? 75.0% of Ikena Oncology shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 5.9% of Ikena Oncology shares are owned by company insiders. Comparatively, 4.7% of Vor Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is IKNA or VOR more profitable? Vor Biopharma's return on equity of 0.00% beat Ikena Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Ikena OncologyN/A -36.88% -33.08% Vor Biopharma N/A N/A N/A Does the MarketBeat Community prefer IKNA or VOR? Vor Biopharma received 19 more outperform votes than Ikena Oncology when rated by MarketBeat users. Likewise, 68.06% of users gave Vor Biopharma an outperform vote while only 60.00% of users gave Ikena Oncology an outperform vote. CompanyUnderperformOutperformIkena OncologyOutperform Votes3060.00% Underperform Votes2040.00% Vor BiopharmaOutperform Votes4968.06% Underperform Votes2331.94% Which has stronger valuation & earnings, IKNA or VOR? Vor Biopharma has lower revenue, but higher earnings than Ikena Oncology. Ikena Oncology is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIkena Oncology$9.16M9.01-$68.17M-$1.23-1.39Vor BiopharmaN/AN/AN/A-$1.65-0.48 Does the media prefer IKNA or VOR? In the previous week, Ikena Oncology had 1 more articles in the media than Vor Biopharma. MarketBeat recorded 2 mentions for Ikena Oncology and 1 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 1.34 beat Ikena Oncology's score of 0.67 indicating that Vor Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ikena Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vor Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend IKNA or VOR? Ikena Oncology currently has a consensus target price of $3.00, suggesting a potential upside of 75.44%. Vor Biopharma has a consensus target price of $11.36, suggesting a potential upside of 1,337.61%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Ikena Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ikena Oncology 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Vor Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, IKNA or VOR? Ikena Oncology has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of -0.4, suggesting that its stock price is 140% less volatile than the S&P 500. SummaryVor Biopharma beats Ikena Oncology on 10 of the 15 factors compared between the two stocks. Ad WealthPressI hate to say I told you soLast month, I openly declared that a Trump Presidency was going to kick off Tesla’s New Bullish Cycle Folks who listened and bought in when I said to are currently crushing it. As a matter of fact, all the trades we’ve opened ever since I made that public declaration have ALL been winners. And it’s simply because this Tesla indicator just flipped green on the stock…Follow this link right away. Get Ikena Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKNA vs. The Competition Export to ExcelMetricIkena OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.53M$3.04B$5.38B$8.84BDividend YieldN/A1.91%5.13%4.09%P/E Ratio-1.3945.50105.9717.81Price / Sales9.01392.401,243.81162.56Price / CashN/A169.3840.2936.29Price / Book0.624.597.086.50Net Income-$68.17M-$41.63M$119.58M$226.22M7 Day Performance1.18%2.62%2.25%4.04%1 Month Performance1.18%-2.46%-2.33%4.94%1 Year Performance4.91%28.25%33.91%29.30% Ikena Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKNAIkena Oncology3.5034 of 5 stars$1.71-1.2%$3.00+75.4%+4.9%$82.53M$9.16M-1.3970VORVor Biopharma2.5536 of 5 stars$0.79-0.2%$11.36+1,329.5%-55.4%$54.56MN/A0.00140Positive NewsXLOXilio Therapeutics1.905 of 5 stars$0.88-4.3%$4.00+354.4%-19.6%$38.70MN/A-0.5373IVAInventiva3.0477 of 5 stars$2.58-3.0%$13.25+413.6%-34.4%$135.40M$18.91M0.00100Analyst ForecastNews CoverageGap DownQTTBQ32 Bio1.6143 of 5 stars$26.66-1.4%$72.33+171.3%N/A$324.72M$1.16M-1.9039DSGNDesign Therapeutics0.6632 of 5 stars$5.68+2.0%$7.00+23.2%+154.3%$321.60MN/A-6.5440KODKodiak Sciences2.979 of 5 stars$6.08+3.1%$3.50-42.4%+157.9%$319.93MN/A-1.6290CYRXCryoport2.8687 of 5 stars$6.34-2.8%$12.50+97.2%-53.2%$313.39M$226.11M-1.951,170Insider TradeCMPSCOMPASS Pathways2.9186 of 5 stars$4.56+2.5%$30.67+572.5%-27.1%$312.00MN/A-2.03120Positive NewsSAGESage Therapeutics4.3758 of 5 stars$5.09+4.9%$12.83+152.1%-73.4%$311.37M$106.40M-0.87690Analyst ForecastVYGRVoyager Therapeutics4.6684 of 5 stars$5.67+4.4%$17.00+199.8%-17.8%$309.73M$163.78M7.97100 Related Companies and Tools Related Companies VOR Competitors XLO Competitors IVA Competitors QTTB Competitors DSGN Competitors KOD Competitors CYRX Competitors CMPS Competitors SAGE Competitors VYGR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IKNA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ikena Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ikena Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
